SUMGEN BIOTECH
Jianjian Biotechnology is an antibody drug developer, specializing in the development of therapeutic antibody drugs and the application of antibodies in immunotherapy and immunodiagnosis. Based on CD&MD innovative antibody research and development technology, it has developed products such as tumor immunotherapy antibody drugs and CART antibodies. .
SUMGEN BIOTECH
Industry:
Biotechnology Clinical Trials Health Care Medical
Founded:
2015-01-01
Address:
Hangzhou, Zhejiang, China
Country:
China
Website Url:
http://www.sumgenbio.com
Total Employee:
101+
Status:
Active
Total Funding:
270 M CNY
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF SSL By Default Mobile Non Scaleable Content HSTS Nginx Alibaba Tencent QQ Mail TrustAsia
Similar Organizations
Bainuo Doctors(Shenzhen Bainuo Mingjihui Network Technology Co)
Bainuo Doctors is a Healthcare Start up Based in Shenzhen.
Gracell Biotechnologies
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
Hangzhou Just Biotherapeutics (Just China)
Hangzhou Just Biotherapeutics is a comprehensive high-tech design company.
Kexin Health Industry Development
A Healthcare Company based in Changsha,China.
Qihan Biotech
Qihan Biotech is a gene-editing organ transplantation technology developer.
Ringpai National Chain Veterinary Hospital
Tianjin Based is a Healthcare Start Up based in Tianjin.
SA Biotech
SA Biotech is a Healthcare company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Viva Biotech
Viva Biotech is a Healthcare Start Up Based In Shanghai.
Yuyi Technology
Yuyi Technology is a hydraulic parts manufacturer.
Current Employees Featured
Founder
Investors List
Hankang Capital
Hankang Capital investment in Series B - Sumgen Biotech
China Biotech
China Biotech investment in Series B - Sumgen Biotech
ZSVC
ZSVC investment in Series B - Sumgen Biotech
Addor Capital
Addor Capital investment in Series B - Sumgen Biotech
Baopu Asset Management
Baopu Asset Management investment in Series B - Sumgen Biotech
JC Capital
JC Capital investment in Series B - Sumgen Biotech
Sinopharm Capital
Sinopharm Capital investment in Series B - Sumgen Biotech
Addor Capital
Addor Capital investment in Series B - Sumgen Biotech
Bank of Communications
Bank of Communications investment in Series B - Sumgen Biotech
Shanghai Haoshuo Investment
Shanghai Haoshuo Investment investment in Series B - Sumgen Biotech
Official Site Inspections
http://www.sumgenbio.com
- Host name: 47.95.33.42
- IP address: 47.95.33.42
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Sumgen Biotech"
尚健生物
重大里程碑！恩朗苏拜单抗注射液（恩舒幸®）国内获批上市！ 2024年6月28日，由杭州尚健生物技术有限公司完成早期研发的恩朗苏拜单抗注射液（商品名：恩舒幸®）获国家药品监督管理局（nmpa）批准上市（国药准字s20240028）.....See details»
尚健生物 - sumgenbio.com
Overview. Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as “Sumgen” or the “company”) is a biotechnology company dedicated to advancing scientific innovation in the …See details»
Sumgen Biotech - Crunchbase Company Profile
Sumgen Biotech is a Healthcare Start Up Based in Hangzhou. Jianjian Biotechnology is an antibody drug developer, specializing in the development …See details»
尚健生物 - sumgenbio.com
2017.12. Sumgen Biotech was selected in“5050 Plan” of Hangzhou High-tech Zone (Binjiang).See details»
Sumgen Biotech Company Profile | Management and Employees …
Www.sumgenbio.com Sumgen Biotech Profile and History Founded in 2015 and based in Hangzhou, Zhejiang, China, Jianjian Biotechnology is an antibody drug developer, specializing …See details»
Hangzhou Shangjian Biotechnology Co., Ltd.
Mar 8, 2025 www.sumgenbio.com. Startups | Holding Company | Subsidiary Company | 2015 | Zhejiang Sheng, China | 100-250 | www.sumgenbio.com. Last update 08 Mar 2025. Overview. …See details»
Sumgen - VentureRadar
"Headquartered in Hangzhou, Sumgen develops antibody drugs for oncology and other severe diseases. Through its proprietary platform and partnerships with leading organisations such as …See details»
尚健生物-动脉网 - vbdata.cn
Dec 30, 2021 杭州尚健生物技术有限公司（以下简称“尚健生物”或“公司”），是一家创新驱动型生物制药企业，致力于创新生物药开发与商业化。公司由原军事医学科学院青年科学家、国家“ …See details»
Sumgen 2025 Company Profile: Valuation, Funding & Investors
Sumgen General Information Description. Developer and manufacturer of innovative antibody drugs for the treatment of tumors and other diseases. The company utilizes computer-aided …See details»
Hangzhou Shangjian Biotechnology Co., Ltd.
了解Hangzhou Shangjian Biotechnology Co., Ltd. (杭州尚健生物技术有限公司)公司的药物管线，治疗领域，技术平台，以及它的19项临床试验, 1篇新闻和5篇文献，疾病领域:肿瘤，血液及淋巴系统疾病，免疫系统疾病，内分泌与代谢疾 …See details»
杭州尚健生物技术有限公司 - 药智数据
药智数据为您提供杭州尚健生物技术有限公司的企业数据查询，查询杭州尚健生物技术有限公司工商注册信息、公司电话、公司地址、公司邮箱网址、公司经营范围、公司产品类型、公司主营 …See details»
Sumgen Biotech - Overview, News & Competitors | ZoomInfo.com
Sumgen Biotech. Business Services · China · <25 Employees. Founded in 2015 and based in Hangzhou, Zhejiang, China, Jianjian Biotechnology is an antibody drug developer, specializing …See details»
尚健生物 - sumgenbio.com
浙江大学生物技术专业学士，免疫学博士，主要从事基因工程抗体研究，拥有近20年抗体研发经验。2014年研制的埃博拉抗体并成功救治英国女兵，受到国家领导人表彰，入选埃博拉疫情防 …See details»
中生尚健生物医药（杭州）有限公司 - 吕明 - 杭州企业名录
中生尚健生物医药（杭州）有限公司，简称：中生尚健生物医药（杭州），位于浙江省杭州市滨江区，公司成立于2020-03-03年，创始人：吕明，公司注册资本为：40,000万(元),所属行业为： …See details»
Hangzhou Sumgen Biotech Co., Ltd. - discovery.patsnap.com
Mar 2, 2023 Discovery Company profile page for Hangzhou Sumgen Biotech Co., Ltd. including technical research,competitor monitor,market trends,company profile& stock symbolSee details»
SUMGEN - Products, Competitors, Financials, Employees, …
Sep 14, 2019 sumgenbio.com. Overview & Products; Financials; People; Founded Year 2015. Stage Series B - II | Alive. Total Raised $71.02M. Last Raised $31.38M | 3 yrs ago. Mosaic …See details»
Sumgen Biotech - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Naobios to Scale Up Production of Sumagen’s HIV Vaccine …
Oct 30, 2024 Naobios achieves a critical development milestone for Sumagen’s HIV-1 vaccine candidate. Scale-up to support phase I/II trials is planned to begin by end of 2025.See details»
尚健生物 - sumgenbio.com
近日，杭州尚健生物技术有限公司申报的“新型生物药物临床前研究—重组高亲和力cd47受体融合蛋白sg404临床前研究项目”获得2020年度浙江省重点研发计划项目立项支持。See details»
Chime Biologics Enters into a Strategic Cooperation Agreement …
鼎康生物与尚健生物签订战略合作协议 【2021年9月24日，武汉】杭州尚健生物技术有限公司（Sumgen Biotech，以下简称“尚健生物”），一家 致力于恶性肿瘤等重大疾病的创新抗体药物 …See details»